IKT icon

Inhibikase Therapeutics

14 hedge funds and large institutions have $10.6M invested in Inhibikase Therapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 4 closing their positions.

Holders
14
Holders Change
+5
Holders Change %
+55.56%
% of All Funds
0.24%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
4
Reduced
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
ACM
1
ACT Capital Management
Pennsylvania
$2.45M 875,000 +875,000 New
KC
2
Kepos Capital
New York
$1.96M 700,000 +700,000 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.32M 470,615 +470,615 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$1.21M 433,300 +333,300 +333%
SM
5
Sabby Management
Florida
$1.18M 421,200 +421,200 New
M
6
Murchinson
Ontario, Canada
$899K 320,947 +320,947 New
AC
7
Antara Capital
New York
$700K 250,000 +250,000 New
ACM
8
Altium Capital Management
New York
$307K 109,749 +109,749 New
ZCA
9
Zeke Capital Advisors
Pennsylvania
$263K 93,800 +75,000 +399%
WAM
10
Warberg Asset Management
Illinois
$252K 90,000 +90,000 New
HF
11
HRT Financial
New York
$42K 15,000 +3,386 +29%
BlackRock
12
BlackRock
New York
$38K 13,571 +13,000 +2,277%
Rockefeller Capital Management
13
Rockefeller Capital Management
New York
$4K 1,500 +1,500 New
Citadel Advisors
14
Citadel Advisors
Florida
-17,857 Closed
Millennium Management
15
Millennium Management
New York
-11,224 Closed
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
-2,000 Closed
TRCT
17
Tower Research Capital (TRC)
New York
-543 Closed
Wells Fargo
18
Wells Fargo
California
$0 12
CFGS
19
Concourse Financial Group Securities
Alabama